Abstract The aim of this study was to determine the levels of plasma fatty acids in patients with peripheral arterial disease and in control subjects and to identify whether any risks of disease related to these differences were influenced by smoking and antioxidant intake. A random sample of 1592 men and women aged 55 to 74 years was selected from the general population (the Edinburgh Artery Study), from which 153 cases of peripheral arterial disease were identified by the presence of intermittent claudication and low ankle systolic pressures at rest and during reactive hyperemia; these were matched by age and sex to 153 control subjects with no evidence of cardiovascular disease. In 113 case and 122 control subjects, fatty acid levels were measured in three plasma fractions (triglyceride, cholesteryl ester, and phospholipid), and smoking habits and dietary antioxidant intake were determined by questionnaire. Arachidonic acid, eicosapentaenoic acid, docosahexaenoic acid, and docosapentaenoic acid (DPA/ T he main dietary essential fatty acids are linoleic acid (18:2 n-6) and a-linolenic acid (18:3 n-3), both found mainly in vegetable oils. Within the body, these parent essential fatty acids are metabolized by a series of reactions to form arachidonic acid and eicosapentaenoic acid (EPA), which are further metabolized to prostacyclins and thromboxanes (Figure) , substances known to exert opposing physiological effects on the cardiovascular system. An important rate-limiting step in the metabolism of linoleic acid and a-linolenic acid is the initial desaturation reaction, where the two parent fatty acids compete for the A-6-desaturase enzyme. This step may also be inhibited by several factors associated with cardiovascular disease, such as high cholesterol levels, catecholamines, high saturated-fat intake, and aging.
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Deficiencies of linoleic acid were first noted in the plasma cholesteryl esters of patients with coronary artery disease by Kingsbury et al 2 in 1969 . Subsequent studies have also shown low levels of linoleic acid to be associated with an increased risk of coronary heart disease, 35 and throughout Europe low levels of linoleic acid are known to be inversely related to the gradient of coronary heart disease. 6 In Scotland, men with coronary heart disease have lower-than-expected levels of adipose linoleic acid, 5 independent of other classic risk factors, including smoking. 7 However, there is some evidence that a low risk of coronary disease is associated with a high intake of n-3 essential fatty acids, 810 and that low levels of several metabolites of both linoleic acid and a-linolenic acid (dihomo--y-linolenic acid [DGLA], arachidonic acid, EPA, and docosahexaenoic acid [DHA]) may be more closely associated with the risk of coronary disease than are the parent essential fatty acids themselves. 81112 In Japan, where there is high consumption of seafood rich in EPA and arachidonic acid, there are lower-than-expected rates of smoking-related coronary heart disease. 13 It is therefore possible that the metabolites of linoleic and a-linolenic acid might attenuate some of the effects of smoking. Few studies, however, have examined the importance of essential fatty acids in the development of peripheral arterial disease, for which cigarette smoking is relatively more important in the etiology than it is in coronary heart disease.
The Edinburgh Artery Study is the first random sample survey in the general population in which levels of essential fatty acids have been measured in subjects with peripheral arterial disease and matched healthy control subjects. The objectives were to determine whether there were any differences in the plasma levels of essential fatty acids in case compared with control subjects and the extent to which the risks of disease related to these differences were influenced by smoking and dietary antioxidants.
Methods

Subject Selection
The Edinburgh Artery Study is a cross-sectional survey of 1592 men and women aged 55 to 74 years selected from the age and sex registers of 10 general practices with catchment populations spread geographically and socioeconomically throughout the city. Details of the study population, recruitment, and prevalence of peripheral arterial disease have been described previously.
14 Each subject completed a detailed questionnaire that included validated questions on social class, 15 cardiovascular history, 16 and smoking history. Information on intake of vitamin C, a-tocopherol, and ^-carotene was obtained using a version of a food-frequency questionnaire used in a previous study 17 ; this comprised a list of food items, and respondents were asked to indicate the frequency of consumption (rarely, monthly, or 1 to 7 times per week). Ethics committee approval was given for this study, and informed consent was obtained from each patient.
Symptomatic peripheral arterial disease was identified using the World Health Organization (WHO)/Rose questionnaire on intermittent claudication, 16 and asymptomatic disease was detected by measuring the ankle-brachial systolic pressure index (ABPI) at rest and the change in ankle systolic pressure during reactive hyperemia. Systolic and diastolic (phase V) blood pressures were taken in the right arm after 10 minutes of rest in the supine position using a random-zero sphygmomanometer. Ankle systolic blood pressures were taken first in the right and then in the left leg using the random-zero sphygmomanometer and a Doppler probe. Where possible, blood flow was detected at the ankle in the posterior tibial artery. In the reactive hyperemia test, ankle systolic pressure was measured in the right and left legs 15 seconds after the release of a cuff that occluded arterial flow above the knee for 4 minutes at approximately 50 mm Hg above systolic pressure. The timing was standardized using an electronic timer.
The presence of peripheral arterial disease was defined by any of the following criteria: an ABPI £0.7, ABPI ^0.9 plus intermittent claudication (WHO questionnaire positive), 16 a percentage drop in ankle pressure after occlusion ^35%, a percentage drop s20% plus claudication, or a percentage drop ^20% plus an ABPI ^0.9. Because these categories had not been used in other studies, the validities were unknown, but results of studies comparing the ABPI and reactive hyperemia separately with angiography would suggest that the classification had adequate face validity.
1819 Subsequent duplex scanning of subsamples of the case and control subjects indicated that the definitions were acceptable. 20 With these criteria, 153 subjects were identified as having significant peripheral arterial disease. These were frequencymatched by age (5-year bands) and sex to 153 control subjects who had no intermittent claudication, an ABPI >0.9, and a percentage drop <20% in both legs, plus no evidence of coronary heart disease detected by the WHO questionnaire 16 or electrocardiogram.
Biochemical Tests
Fatty acid levels were estimated from samples of fasting venous blood in 113 (74%) of the case subjects and 122 (80%) of the control subjects. The triglyceride, cholesteryl ester, and phospholipid fractions were separated by thin-layer chromatography. Each fraction was methylated, and the fatty acid methyl esters were measured by gas chromatography; the analysis was performed by Scotia Pharmaceuticals, Guildford, Surrey, UK, where laboratory staff were blinded to whether the samples were derived from case or control subjects. Results were expressed as the concentration of each fatty acid in milligrams per 100 mg in the lipid fraction as previously described. 21 Combining results from case and control subjects, the physiological coefficient of variation ranged from 0.09 to 11.25; the methodological coefficient of variation ranged from 0.02 to 0.5.
Levels of the following fatty acids were determined as listed: n-6 series: linoleic acid ( In all 153 case and 153 control subjects, serum cholesterol, high-density lipoprotein (HDL) cholesterol, and triglyceride concentrations were measured in fasting venous blood (Cobas Bio Analyser, Roche Products). Quality control was monitored by means of blind duplicate samples taken intermittently throughout the study. Laboratory standardization was carried out using commercially available standards (Wellcome scheme), and quality was assessed by examining systematic and random error against two control materials (Precipath universal bovine serum and pooled donated sera).
Statistical Analysis
Data were analyzed on the Edinburgh University mainframe computer using SPSS-X 22 and BMDP 23 statistical software packages. Mean and percentage levels of disease characteristics and risk factors were compared in those 113 case and 122 control subjects who were available for fatty acid analysis. These levels were compared with those in the original 153 case and 153 control subjects from which they were derived in terms of age, sex, cigarette smoking, intermittent claudication, and mean ABPI. The subgroups available for fatty acid analysis were almost identical to the original groups, with no significant differences.
"Energy-adjusted" nutrient intakes were obtained from the residuals of the regression of each of the nutrients with total energy intake as the predictor. Non-HDL cholesterol (ie, total minus HDL cholesterol) and HDL cholesterol were used in the analysis. Differences in smoking status (current smokers versus exsmokers) were determined using the x 2 test with two degrees of freedom, and differences in antioxidant intake, lipid levels, and lifetime smoking using pack-years (average number of packs of 20 cigarettes per day multiplied by the number of years as a smoker) were determined using the t test. Although mean levels are reported, differences between the concentrations of fatty acids were determined by comparing median values, because of skewed distributions, and testing for statistical significance using the Mann-Whitney test.
Spearman correlation coefficients were calculated to detect associations between fatty acids and smoking habits in case and control subjects separately. A logistic regression analysis was performed for case and control subjects for those fatty acids that showed significant differences on univariate analysis; the analyses were adjusted for age and sex because the case and control subjects were frequency-matched for age and sex. A logarithmic transformation was used for EPA because of a skewed distribution. Adjustments were made for vitamin C intake, current smoking, serum HDL cholesterol, non-HDL cholesterol, and triglyceride. A logistic regression analysis was also performed by current smoking status, adjusting for age, sex, vitamin C intake, and those fatty acids that showed significant differences on univariate analysis. Table 1 shows that current and exsmoking habits, non-HDL cholesterol, and triglyceride levels were significantly higher in the case subjects, whereas vitamin C intake and HDL cholesterol were significantly lower. There were no significant differences in the intake of other antioxidant vitamins, including a-tocopherol and /3-carotene. Tables 2 through 4 show the mean values of fatty acid levels in case and control subjects for the triglyceride, cholesteryl ester, and phospholipid fractions. There were no significant differences between the levels of saturated or monounsaturated fatty acids in case and control subjects in any of the fractions. In the triglyceride fraction (Table 2) , both case and control subjects Significant differences in risk factors between cases and controls: *P<.05; t P < . 0 1 ; tP<.OO1.
Results
had relatively high concentrations of the parent essential fatty acids, linoleic acid and a-linolenic acid, compared with low concentrations of all the metabolites. The only statistically significant difference between case and control subjects occurred with arachidonic acid, which was lower in the cases. The mean linoleic acid concentration was also slightly lower in the case subjects, but the difference was not significant. In the cholesteryl ester fraction (Table 3) , there were also relatively low concentrations of metabolites of linoleic acid in cases and controls. The levels of both linoleic acid and arachidonic acid were again slightly lower in the case than control subjects, but both differences were nonsignificant. In contrast, the concentration of a-linolenic acid was exceeded by its metabolite EPA, and both EPA and DHA were significantly lower in the case subjects than in controls. In the phospholipid fraction (Table 4) , all metabolites of linoleic acid were detected but, with the exception of DGLA and arachidonic acid, in relatively low concentrations. Arachidonic acid levels were again not significantly lower in the case subjects. In the n-3 series, the three metabolites of a-linolenic acid were present in relatively large concentrations and were .54
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In the case subjects, there were significant correlations between current smoking and lower levels of aiachidonic acid (r=-.23), EPA (r=-.26), and DHA (r= -.23) (P< .05) and with increased levels of oleic acid (r=.3O) (P<.001) in the cholesteryl ester fraction. In the phospholipid fraction, DHA showed a similar negative correlation with smoking habits, but there were no other significant associations in this or the triglyceride fraction. In the control subjects, there were no significant correlations between smoking and fatty acid levels in any of the fractions. These correlations were similar when using lifetime smoking (pack-years) instead of current smoking. Table 5 shows the odds ratios of disease for those fatty acids that were found to be significantly different between case and control subjects (Tables 2 through 4 ). On adjusting for vitamin C intake, only DHA and DPA/n-3 remained significantly different. On adjusting for current smoking habits, only DPA/n-3 and arachidonic acid remained significantly related to disease; if lifetime smoking was used instead of current smoking, only DPA/n-3 remained significant (P<.05). Further adjustment for serum triglyceride and HDL and non-HDL cholesterol did not affect the relation for DPA/n-3.
The odds ratio of disease in current smokers, adjusted for age and sex, was 13.8 (95% confidence interval, 5.91 to 32.1). Table 6 shows the effect of adjusting this for individual fatty acids and vitamin C intake. On adjusting for fatty acids, there were small decreases in the odds ratios for all except DPA/n-3, where the odds increased from 13.8 to 14.4. In most cases, further adjustment for vitamin C intake slightly increased the odds. 
Discussion
The fatty acid composition of any lipid fraction is influenced by three major factors: the dietary intake of fatty acids, the metabolic regulation of fatty acid synthesis, and the preferential incorporation of some fatty acids into different fat classes. 24 Each lipid fraction has a characteristic fatty acid composition, and it is therefore important to analyze separate fractions rather than total plasma lipids. 24 In this study, fatty acid levels were measured in three plasma fractions: the triglyceride fraction, which primarily reflects recent dietary intake, plus the phospholipid and cholesteryl ester fractions, which are more independent of recent intake and are probably better indicators of the longer-term composition of dietary fats. 25 Several epidemiological studies have concentrated on measuring adipose tissue fatty acids, but this method provides information mostly about long-term nutritional supply of linoleic acid and provides little information with respect to subsequent metabolism, as levels of metabolites are very low in adipose tissue. 26 In this study, there were few differences in the levels of n-6 fatty acids between case and control subjects. Linoleic acid levels were not found to be lower in those subjects with peripheral arterial disease, although this might have been expected because low levels have been associated with coronary heart disease 6 and also because linoleic acid reduces low-density lipoprotein cholesterol 27 and platelet aggregability, 28 factors associated with the development of atheroma. 29 A study of coronary heart disease in Scottish men showed low concentrations of the metabolite DGLA to be more significantly related to disease than those of linoleic acid, 30 but there was no reduction in DGLA in those subjects with peripheral arterial disease in this study. Arachidonic acid, however, was significantly lower in the triglyceride fraction in the case subjects, although this difference disappeared on adjusting for smoking.
The most significant differences between case and control subjects occurred in the levels of n-3 fatty acids. There were, however, no differences between levels of the parent compound, a-linolenic acid, suggesting that the dietary intake of a-linolenic acid was similar in those with peripheral arterial disease and control subjects. In contrast, highly significant differences occurred in the phospholipid and cholesteryl ester fractions in EPA, DPA/n-3, and DHA, all of which were lower in the cases, as might have been expected from other studies. 7 EPA and DHA are known to inhibit the formation of arachidonic acid from linoleic acid, 1 thus increasing the relative concentration of EPA as a substrate for cyclooxygenase (Figure) . However, the ratios of linoleic acid to arachidonic acid were similar in cases and controls, suggesting that the metabolism of linoleic acid was not significantly impaired in those with peripheral arterial disease. EPA competes with arachidonic acid for the cyclooxygenase enzyme, thus forming different prostacyclins and thromboxanes that produce a more vasodilatory state with less platelet aggregation. 1 The ratio of EPA to arachidonic acid in the cholesteryl ester fraction was significantly lower in the case than control subjects, suggesting that less EPA may be formed in those with peripheral arterial disease. Other mechanisms by which the presence of n-3 fatty acids may prevent the formation of atheroma include the reduction of triglyceride 31 and low-density lipoprotein levels, 32 lowering blood viscosity, 33 and increasing fibrinolytic activity. 34 Therefore, the difference in n-3 fatty acid levels between case and control subjects may be partly responsible for the different disease status.
Vitamin C intake was significantly lower in the case than control subjects, confirming other studies that have shown deficiencies in patients with coronary and peripheral vascular disease. 35 - 36 We might also have expected the case subjects to show deficiencies in their intake of the other important dietary antioxidants, vitamins A and E, 37 although the lack of significant differences may have occurred primarily because of inaccuracies in the food-frequency questionnaire, particularly related to problems in estimating portion sizes. It is therefore possible that direct measurement of antioxidant levels in the plasma might have detected a difference between case and control subjects, but unfortunately this analysis could not be included. Vitamin C is a naturally occurring antioxidant, known to protect polyunsaturated fatty acids from peroxidation, and thus some of the differences in essential fatty acid levels between case and control subjects might have been expected to be explained by vitamin C intake. However, on adjusting for vitamin C, there was only a slight decrease in the odds ratios, which was not statistically significant.
On adjusting for smoking, however, only DPA/n-3 in the plasma phospholipid fraction and arachidonic acid in the triglyceride fraction remained significantly lower in the case subjects, suggesting that some of the differences in fatty acid levels may be related to smoking habits. Smokers are known to have lower adipose tissue levels of the parent fatty acid linoleic acid, 7 and in a dietary survey using a 7-day prospective weighed record, current cigarette smokers had a significantly lower intake of linoleic acid than nonsmokers, independent of social class. 38 However, as far as we are aware, this is the first report of a possible effect of smoking on essential fatty acid metabolites. Although smoking explained most differences between case and control subjects, DPA/n-3 remained significantly lower in the case subjects even after also adjusting for triglycerides and HDL and non-HDL cholesterol. On adjusting for DPA/n-3 in the logistic regression by current smoking, it was the only fatty acid that increased the odds of disease, suggesting that it has a protective effect. This significant association between DPA/n-3 and peripheral arterial disease has not previously been reported, although EPA and DHA have been shown to be lower in those with coronary heart disease. 4 -5 ' 7810 ' 11 Unlike EPA and DHA, DPA/n-3 is not found in fatty fish and may therefore be less affected by dietary differences in the smokers.
These observations raise the interesting hypothesis that the adverse effects of smoking might be caused partly by an effect on essential fatty acid metabolism. It is known that the gas and tar phases of tobacco smoke contain many reactive oxidizing species, 39 and both animal 40 and human 41 studies have shown that exposure to cigarette smoke has a deleterious effect on antioxidant status. Thus, the enhanced free-radical load of smokers, especially when combined with a low antioxidant intake, will result in an increased peroxidation of essential fatty acids and will consequently reduce the availability of these fatty acids. This leads to the further hypothesis that direct provision of metabolites of linoleic and a-linolenic acids might attenuate some of the effects of smoking. An effect of diet on the adverse consequences of smoking has already been suggested in the case of Japan, where there is a very high prevalence of smoking with lower-than-expected rates of smokingrelated cancer and coronary heart disease. 13 In the case of pancreatic cancer in Japan, a case-control study has shown that cigarette smoking is positively associated with the disease, whereas the consumption of seafood, which will provide EPA and related n-3 acids as well as arachidonic acid in the case of crustaceans, is negatively associated with the disease. 42 For those who cannot abandon smoking, the possible effects of appropriate essential fatty acid supplementation could be tested in controlled trials.
In conclusion, although lower levels of linoleic acid and arachidonic acid were identified in subjects with peripheral arterial disease compared with healthy control subjects, the largest differences occurred in fatty acids of the n-3 series. EPA, DPA/n-3, and DHA were all significantly lower in case than control subjects, but only DPA/n-3 showed an association with disease that was independent of smoking habits, and only DPA/n-3 reduced the risks associated with smoking. It is therefore possible that some of the adverse effects associated with smoking may be partly mediated by differences in essential fatty acid metabolism.
